SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-24-015390
Filing Date
2024-04-19
Accepted
2024-04-19 17:20:14
Documents
17
Period of Report
2024-04-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 61444
2 ex4-13.htm EX-4.13 49390
3 ex99-1.htm EX-99.1 13364
4 ex99-1_001.jpg GRAPHIC 2983
  Complete submission text file 0001493152-24-015390.txt   364332

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE cldi-20240414.xsd EX-101.SCH 3813
6 XBRL DEFINITION FILE cldi-20240414_def.xml EX-101.DEF 26683
7 XBRL LABEL FILE cldi-20240414_lab.xml EX-101.LAB 36817
8 XBRL PRESENTATION FILE cldi-20240414_pre.xml EX-101.PRE 25307
20 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5925
Mailing Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 4475 EXECUTIVE DRIVE SUITE 200 SAN DIEGO CA 92121 858-794-9600
Calidi Biotherapeutics, Inc. (Filer) CIK: 0001855485 (see all company filings)

IRS No.: 862967193 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40789 | Film No.: 24858948
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)